AbbVie's Commitment to Gastroenterology and Hepatology Showcased at Digestive...
NORTH CHICAGO, Ill., May 12, 2015 /PRNewswire/ -- AbbVie (NYSE: ABBV) announced that 18 abstracts in its gastroenterology and hepatology programs will be presented at Digestive Disease Week® (DDW)...
View ArticleMerck Announces Results From Phase 3 Studies of ZEPATIER(TM) (Elbasvir and...
Merck (NYSE:MRK), known as MSD outside of the United States and Canada, today announced the presentation of results from two Phase 3 clinical trials evaluating ZEPATIER™ (elbasvir and grazoprevir)...
View ArticleMerck Announces Results From Phase 3 Studies of ZEPATIER™ (Elbasvir and...
(Source: Merck & Co Inc) KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside of the United States and Canada, today announced the presentation of results from two Phase 3...
View ArticleOngoing Real World Study Reports High Sustained Viral Response Rates with...
(Source: AbbVie Inc) - Interim results from the independent AMBER study demonstrated 98 percent (n=39/40) SVR(12) rate in patients who completed a 12- or 24-week treatment regimen and 12 weeks...
View ArticleAbbVie Presents New Data for its Investigational Hepatitis C Treatment in...
NORTH CHICAGO, Ill., May 26, 2015 /PRNewswire/ -- AbbVie (NYSE: ABBV) presented new results from the Phase 3 GIFT-I study of its investigational, all-oral, interferon (IFN)- and ribavirin (RBV)-free,...
View ArticleU.S. FDA Grants Priority Review to AbbVie for Investigational, All-Oral,...
NORTH CHICAGO, Ill., April 24, 2015 /PRNewswire/ -- AbbVie (NYSE: ABBV) has announced that the U.S. Food and Drug Administration (FDA) has accepted its New Drug Application (NDA) and granted priority...
View ArticleU.S. FDA Grants Priority Review to AbbVie for Investigational, All-Oral,...
- The New Drug Application (NDA) was accepted by the U.S. Food and Drug Administration (FDA) and is based on results from the PEARL-I study, which demonstrated up to 100 percent sustained virologic...
View ArticleU.S. FDA Grants Priority Review to AbbVie for Investigational, All-Oral,...
(Source: AbbVie Inc) - The New Drug Application (NDA) was accepted by the U.S. Food and Drug Administration (FDA) and is based on results from the PEARL-I study, which demonstrated up to 100 percent...
View ArticleEnanta Announces SVR12 results of 95% from AbbVie’s GIFT-1 Study in...
(Source: Enanta Pharmaceuticals Inc) Sustained virologic response 12 weeks post-treatment (SVR12) of 91 percent was achieved in Japanese patients with genotype 1b (GT1b) hepatitis C virus (HCV)...
View ArticleAbbVie's VIEKIRAX® (ombitasvir/paritaprevir/ritonavir tablets) Receives...
NORTH CHICAGO, Ill., Sept. 28, 2015 /PRNewswire/ -- AbbVie (NYSE: ABBV), a global biopharmaceutical company, today announced that the Japanese Ministry of Health, Labour and Welfare (MHLW) approved...
View ArticleAbbVie Presents New Data for its Investigational Hepatitis C Treatment in...
(Source: AbbVie Inc) - Primary endpoint of 95 percent and secondary endpoint of 91 percent SVR12 achieved in genotype 1b hepatitis C virus infected Japanese patients without and with compensated...
View ArticleEnanta Pharmaceuticals Announces Data Presentations on Regimens Containing...
(Source: Enanta Pharmaceuticals Inc) Enanta Pharmaceuticals Announces Data Presentations on Regimens Containing Protease Inhibitors Paritaprevir and ABT-493 at The International Liver Congress™ 2015...
View ArticleAbbVie's VIEKIRAX® (ombitasvir/paritaprevir/ritonavir tablets) Receives...
(Source: AbbVie Inc) NORTH CHICAGO, Ill., Sept. 28, 2015/PRNewswire / -- AbbVie (NYSE: ABBV), a global biopharmaceutical company, today announced that the Japanese Ministry of Health, Labour and...
View ArticleEnanta Announces CHMP Grants Positive Opinion for an Eight-Week Treatment...
CHMP opinion is a step closer to the approval of an eight-week regimen of VIEKIRAX + EXVIERA for previously untreated genotype 1b (GT1b) chronic hepatitis C virus (HCV) patients with minimal to...
View ArticleAbbVie to Present Data on VIEKIRAX® (ombitasvir/paritaprevir/ritonavir...
(Source: AbbVie Inc) Mar 30, 2016 NORTH CHICAGO, Ill., March 30, 2016 /PRNewswire / -- AbbVie (NYSE: ABBV), a global biopharmaceutical company, today announced that 25 abstracts have been accepted for...
View ArticleAbbVie Announces New Phase 3b Results in Genotype 1b Chronic Hepatitis C...
NORTH CHICAGO, Ill., June 24, 2015 /PRNewswire/ -- AbbVie (NYSE: ABBV), a global biopharmaceutical company, today announced TURQUOISE-III study results demonstrating 100 percent (n=60/60) sustained...
View ArticleAbbVie Announces Real-World Data with VIEKIRAX®...
BARCELONA, Spain, April 15, 2016 /PRNewswire/ -- AbbVie (NYSE: ABBV), a global biopharmaceutical company, today announced new real-world data showing 96 percent of genotype 1 (GT1) patients (n=486/505...
View ArticleEnanta Pharmaceuticals Announces Preliminary Data from AbbVie’s Phase 3b...
(Source: Enanta Pharmaceuticals Inc) Enanta Pharmaceuticals Announces Preliminary Data from AbbVie's Phase 3b RUBY-I Study in Chronic Hepatitis C Patients with Renal Impairment Presented at The...
View ArticleEnanta Pharmaceuticals Announces Data on Eight-Week Treatment of AbbVie’s...
(Source: Enanta Pharmaceuticals Inc) AbbVie reports 98 percent of previously untreatedgenotype 1b (GT1b) chronic hepatitis C virus (HCV) infected patients without cirrhosis achieved SVRin Phase 3b...
View ArticleAbbVie Announces New Phase 3b Results in Genotype 1b Chronic Hepatitis C...
- 100 percent SVR(12) rate achieved with VIEKIRAX® (ombitasvir/paritaprevir/ritonavir tablets) + EXVIERA® (dasabuvir tablets) without ribavirin(1) NORTH CHICAGO, Ill., June 24, 2015 /PRNewswire/ --...
View Article